triple negative breast cancer

[TransThera Sciences] TransThera Sciences Inc. announced that the US FDA has granted Fast Track Designation to its Phase II stage product TT-00420 for the treatment of patients with Cholangiocarcinom who have no standard treatment options.

[Communications Biology] Investigators showed that first-in-class Leukemia Inhibitory Factor Receptor (LIFRα) inhibitor EC359 could enhance the therapeutic efficacy of histone deacetylase inhibitors (HDACi) against TNBC.

[Cell Metabolism] The authors reported that a fasting-mimicking diet activated starvation escape pathways in TNBC cells, which could be identified and targeted by drugs. They found that metastatic TNBC patients with lower glycemia survived longer than those with higher baseline glycemia.

[Nature] Researchers showed that discoidin domain receptor 1 (DDR1), a collagen receptor with tyrosine kinase activity, instigated immune exclusion by promoting collagen fiber alignment.

[British Journal of Cancer] Researchers demonstrated that KIT was a downstream effector of TCOF1 in mediating Triple-negative breast cancer stemness.

[npj Breast Cancer] The authors demonstrated that Trop2 is overexpressed in TNBC, and that Trop2 was downregulated which delayed TNBC cell and tumor growth that supported the oncogenic role of Trop2 in breast cancer.